Decoding MicroRNA-155: How This Tiny Molecule Could Revolutionize Colon Cancer Treatment
"Scientists uncover the critical role of microRNA-155 (miR-155) in colon cancer, paving the way for innovative therapies that target the disease at its core."
Colon cancer remains a significant health challenge worldwide, prompting researchers to explore innovative treatment avenues. Among these, microRNAs (miRs), small non-coding RNA molecules, have emerged as key players in regulating gene expression and influencing various cellular processes. One such microRNA, miR-155, has been implicated in numerous cancer types, but its precise role in colon cancer has remained elusive – until now.
A recent study published in Experimental and Therapeutic Medicine sheds light on the intricate functions of miR-155 in colon cancer cells. The research team investigated how miR-155 affects cell proliferation, cell cycle progression, apoptosis (programmed cell death), and migration – all critical factors in cancer development and spread. Their findings reveal that miR-155 acts as an 'oncomiR' in colon cancer, promoting the growth and survival of cancer cells.
This article breaks down the key findings of this study, explaining how miR-155 manipulates cellular processes to fuel colon cancer progression. We will also explore the potential of targeting miR-155 as a novel therapeutic strategy for combating this disease.
CRC’s Global Burden
Colorectal cancer involves uncontrolled proliferation of glandular epithelial cells in the colon or rectum. It is among the most commonly diagnosed cancers and a leading cause of death worldwide, with metastasis an important predictor of patient survival. A 2023 review reports more than 600,000 global CRC-related deaths per year, while recent research continues to examine microRNAs as diagnostic and therapeutic tools.
Treatment Gaps
Surgical resection is typically considered the ideal treatment for CRC when the tumor can be completely removed. However, the cited review reports that a quarter of patients are diagnosed at an advanced stage with distant metastasis, making surgery more difficult and reducing overall survival. miRNA-based therapies may offer targeted treatment by modulating miRNA expression, but delivery systems and long-term safety remain unresolved challenges.
How miRNAs Became Central
MicroRNAs are small noncoding RNAs that can bind target messenger RNA and reduce target-protein production through translation inhibition, messenger-RNA cleavage, or degradation. Research has consequently examined their role in CRC progression, chemoradiotherapy, screening, diagnosis, and prognosis. The cited 2025 review also describes miRNAs as capable of functioning as either tumor suppressors or oncogenes.
What Did the Researchers Discover About MiR-155's Role in Colon Cancer?
The researchers conducted a series of experiments using colon cancer cell lines to investigate the effects of manipulating miR-155 levels. They used techniques like MTT assays (to measure cell proliferation), colony formation assays (to assess the ability of cells to form colonies), cell cycle analysis (to determine the distribution of cells in different phases of the cell cycle), and wound healing assays (to evaluate cell migration).
- MiR-155 Promotes Proliferation: Increasing miR-155 levels significantly enhanced the proliferation of colon cancer cells.
- MiR-155 Enhances Colony Formation: Cells with higher miR-155 levels exhibited a greater capacity to form colonies, indicating enhanced survival and growth potential.
- MiR-155 Accelerates Cell Cycle Progression: MiR-155 pushed colon cancer cells through the cell cycle more rapidly, leading to uncontrolled growth.
- MiR-155 Inhibits Apoptosis: Elevated miR-155 levels protected cancer cells from programmed cell death, allowing them to survive longer.
- MiR-155 Boosts Migration: MiR-155 promoted the migration of colon cancer cells, suggesting a role in metastasis (the spread of cancer to other parts of the body).
miR-155’s Expanding Role
Recent work identifies miR-155 as a significant participant in colorectal cancer biology. One cited study reports that miR-155 regulates colon cancer cell behavior by targeting CBL, while a 2025 review describes miRNA-155 as having dual effects in CRC, including promoting drug resistance. These findings place miR-155 within a broader research focus on tumorigenesis, metastasis, and chemotherapy resistance.
Evidence Still Has Limits
The cited colon-cancer study reports that CBL is a direct target of miR-155 and that this interaction may affect proliferation, migration, cell-cycle behavior, and apoptosis. Its wording presents these effects as a study-based possibility rather than a definitive clinical conclusion. A related report states that all experiments were performed three times and that results were expressed as mean plus or minus standard deviation, underscoring the experimental basis of the evidence.
From Biomarkers to Therapies
MicroRNA research spans different cancer contexts and applications. In cervical cancer cells, one cited analysis observed 123 differentially expressed human microRNAs, with 64 over-expressed and 59 under-expressed. In colorectal cancer, reviews emphasize miRNAs’ effects on proliferation, angiogenesis, apoptosis, chemoresistance, radiotherapy response, diagnosis, prognosis, and treatment response, while clinical-trial research evaluates their potential as biomarkers and therapeutic targets.
The Future of Colon Cancer Treatment: Targeting MiR-155
This study's identification of miR-155 as an oncomiR in colon cancer opens exciting new avenues for therapeutic intervention. The researchers further identified casitas B-lineage lymphoma (CBL), an E3 ubiquitin ligase, as a key target of miR-155. CBL normally acts as a tumor suppressor, but miR-155 effectively silences it, removing a critical safeguard against cancer development. By targeting miR-155, scientists hope to restore CBL function and disrupt the processes that fuel colon cancer growth. Further research is needed to develop safe and effective miR-155-targeted therapies, but this study represents a significant step forward in the fight against colon cancer.
Promise Meets Complexity
MicroRNAs are being investigated as regulatory molecules with potential diagnostic and therapeutic value in CRC. However, the cited review notes that prognosis remains poor for patients with advanced CRC despite combinations of surgery, radiotherapy, chemotherapy, and targeted therapy. This contrast supports a measured interpretation: miRNA strategies may complement existing treatment, but their clinical value must be established against the limitations of current care.
Toward Earlier Detection
Future CRC research is focused on improving early detection and developing innovative treatment strategies. A 2024 review identifies miRNAs as small noncoding regulators involved in CRC pathogenesis and examines their deregulation in precancerous disease. Their potential as emerging biomarkers could support screening, diagnosis, prognosis, and treatment development, although the cited material does not establish that any single miRNA is ready for routine clinical use.